RNA Booster Sequence Enhances Transgene Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current RNA vectors for transient expression, particularly retroviral vectors, face challenges such as low efficacy due to rapid degradation of RNA molecules and the need for high vector doses to achieve significant transgene expression, which is undesirable for in vivo applications.
Innovation Solution
Incorporation of an artificial 9-nucleotide RNA Booster sequence, such as mmsknkkkm, upstream of a transgene within a non-viral or viral vector, particularly a retroviral vector, to enhance transgene expression levels without requiring high vector doses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high vector doses are administered to compensate for rapid RNA degradation, then transgene expression levels can be improved, but adverse effects and safety concerns increase
Solution Approach 1:
The patent changes the sequence parameters of the RNA molecule by incorporating the RNA Booster sequence (mmsknkkkm pattern) to enhance translation efficiency. This allows achieving high transgene expression with lower vector doses, thereby reducing adverse effects while maintaining expression reliability.
Solution Approach 2:
The RNA Booster sequence acts as an intermediary element between the transgene and the ribosome. It contains specific structural features (stem-loop structure with conserved nucleotides) that facilitate efficient translation initiation and elongation, enabling high expression without requiring high vector doses.
2Object-affected harmful factors
If non-viral RNA vectors are used to avoid genotoxicity, then safety is improved, but transfection rate and RNA protection against degradation deteriorate
Solution Approach 1:
The patent uses a self-limiting RNA molecule that does not integrate into the host genome, avoiding genotoxicity. The RNA is designed to be transient and degradable, providing temporary expression without long-term genomic persistence, thus balancing safety with effective transient transfection.
Solution Approach 2:
The RNA vector combines multiple functional elements: the RNA Booster sequence for translation enhancement, the transgene coding sequence, and appropriate UTRs. This composite structure optimizes both translation efficiency and safety by maintaining non-integrating characteristics while improving transfection effectiveness.
3Device complexity
If retroviral vectors with detective RT activity are used for transient expression, then transgene expression can be achieved without DNA intermediate, but expression levels remain weak and require high vector doses
Solution Approach 1:
The patent modifies the retroviral vector parameters by incorporating the RNA Booster sequence into the RNA genome. This changes the translational parameters of the vector, enabling strong cap-dependent translation initiation and significantly improving transgene expression levels without requiring high vector doses or complex DNA intermediates.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The RNA Booster significantly improves transgene expression levels in host cells, as demonstrated by increased GFP expression in various cell types and prolonged expression duration, reducing the need for high vector doses and minimizing adverse effects.
Implementation Method 1
the presence of this RNA Booster upstream of a transgene highly improved transgene expression in various host cells
Implementation Method 2
observed very weak cap-dependent translation initiation from standard lentiviral vector genomes
Data Source
AI summary
A method of treating skin and/or skin appendages in a subject in need thereof, which includes administering to the subject a ribonucleic acid (RNA) molecule including, from 5′ to 3′: an RNA Booster sequence that includes or is the following ribonucleic acid sequence: mmsknkkkm, wherein: “m” indicates an adenine (a) or cytosine (c); “s” indicates a guanine (g) or a cytosine (c); “k” indicates a guanine (g) or a uracyl (u); “n” indicates any nucleotide; and a sequence of interest.